RxDoctor Payments Data

Mark Mullen, MD

Internal Medicine · Feasterville Trevose, PANPI 1679581870

Payments from drug & device makers

$838in general payments, 2019–2025

Across 50 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$158
  • Amgen$132
  • Pfizer$94
  • Amarin Pharma, Inc.$89
  • Sanofi Pasteur Inc.$59
  • GSK$51
  • plus $255 from 10 others

What the payments were for

  • Food & beverage$838100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$838 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$59,718
Medicare patients
249
Services billed
948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban154$101,475
JardianceEmpagliflozin85$57,591
MounjaroTirzepatide38$46,917
FarxigaDapagliflozin Propanediol40$37,998
OzempicSemaglutide26$34,273
TrulicityDulaglutide28$31,509
Synjardy XrEmpagliflozin/Metformin Hcl34$31,234
MyrbetriqMirabegron45$19,704
XareltoRivaroxaban22$16,620
RybelsusSemaglutide14$13,678
Icosapent Ethyl24$10,604
JanuviaSitagliptin Phosphate45$9,150
Rosuvastatin Calcium374$8,600
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$6,424
Mesalamine33$5,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$94$102,904166 claims
Novo NordiskOzempic, Rybelsus$158$47,95140 claims
AstraZenecaFarxiga, Crestor$16$41,64154 claims
Johnson & JohnsonXarelto$14$16,62022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Feasterville Trevose

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →